Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Plus Bevacizumab and Chemotherapy for EGFRm+ NSCLC Post-TKI
NCT06334757Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06334757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06334757.